The use of sulprostone, a prostaglandin E2 derivative, in intrauterine fetal death and therapeutic abortion.
The prostaglandin E2 derivative Sulprostone was used in the management of intrauterine fetal death and in therapeutic abortion in advanced pregnancy. While with extraamniotic administration there was a success rate of 50% after 24 hours, the rate of success was 86% after intramuscular administration. A cervix-ripening effect was not always observed by means of intracervical injection of Sulprostone. Such pre-treatment of the cervix did not improve the induction-abortion time after intramuscular administration of Sulprostone. Side effects were only slight following Sulprostone.
D000032:Abortion, Therapeutic; D000293:Adolescent; D000328:Adult; D000650:Amnion; D002584:Cervix Uteri; D015232:Dinoprostone / Q000031:analogs & derivatives*; D005260:Female; D005313:Fetal Death / Q000188:drug therapy*; D006801:Humans; D007267:Injections; D007273:Injections, Intramuscular; D007751:Labor, Induced; D011247:Pregnancy; D011459:Prostaglandins E, Synthetic / Q000008:administration & dosage / Q000627:therapeutic use*
D011459:Prostaglandins E, Synthetic; C016767:sulprostone; D015232:Dinoprostone